Sham Mailankody, MBBS, summarizes recent data from the KarMMa-3 trial investigating ide-cel in patients with early relapsed/refractory multiple myeloma.
Case: A 70-Year-Old Man with Early Relapse Multiple Myeloma
Clinical Presentation:
Prior Treatments:
Follow up and Clinical Workup at Relapse:
Isa-KRd Induction Yields Deep Responses, High MRD Negativity in NDMM
September 27th 2024Isa-KRd showed deep responses, high MRD negativity rates, and manageable safety in patients with newly diagnosed, transplant-eligible multiple myeloma, as per interim analysis of the IFM2020-02 MIDAS study.
Read More
Breakthrough for Advanced Myeloma? Talquetamab/Teclistamab Delivers Durable Responses
September 27th 2024A new drug combination, talquetamab and teclistamab, shows promising results in treating patients with heavily pretreated multiple myeloma, with high response rates and durable responses.
Read More
Efficacy of Cilta-Cel Is Maintained in Early Relapsed Multiple Myeloma
September 20th 2024During a Case-Based Roundtable® event, Samer A. Al'Hadidi, MD, MS, discussed the CARTITUDE-4 trial of cilta-cel in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More